Wockhardt Ltd. swung to a net profit of ₹20 crore in Q3FY25, a sharp recovery from the ₹86 crore loss reported in the same period last year.

The pharmaceutical and biotechnology company, which manufactures drugs, vaccines, and other healthcare products, also posted steady revenue growth during the quarter.

Revenue rose 3% year-on-year to ₹721 crore from ₹701 crore.

Meanwhile, earnings before interest, tax, depreciation, and amortisation (EBITDA) surged multifold to ₹128 crore, reflecting a 246% jump from ₹37 crore in Q3 FY24. The sharp rise in EBITDA highlights the company’s improving operational efficiency and cost controls.

Also read: Aurobindo Pharma Q3 Results: Revenue beats estimates, profit and margin under pressure

Wockhardt, which also operates a chain of hospitals, has been focusing on strengthening its global presence while optimising its product portfolio.

Post results, Wockhardt shares climbed to the day’s high of ₹1,675.10, but profit booking dragged the stock nearly 3% down to ₹1,601.30 on the BSE at 2:22 pm.